| Overview |
| bs-12066R-Cy3 |
| GABA A Receptor beta 2 + 3 Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GABA A Receptor beta 2 + 3 |
| 301-400/512 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| GABA A receptor beta 3 subunit; GABA alpha receptor beta 2 subunit; GABAA receptor beta 2 subunit; GABAA receptor beta 3 subunit; GABAA receptor subunit beta 2; GABAA receptor subunit beta 3; GABRB2; GABRB3; Gamma Aminobutyric Acid A receptor beta 3; Gamma Aminobutyric Acid receptor beta 2 subunit; Gamma aminobutyric acid receptor subunit beta 2; Gamma aminobutyric acid receptor subunit beta 3; Testis gamma aminobutyric acid receptor subunit beta 3; GBRB2_HUMAN. |
| Gamma-aminobutyric acid type A (GABAA) receptors are members of the neurotransmitter ligand-gated ion channels that mediate neuronal inhibition on binding GABA. The effects of GABA on GABAA receptors are modulated by a range of therapeutically important drugs, including barbiturates, anaesthetics and benzodiazepines. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz